对于糖尿病的肠道微生物群调节疗法应该是个性化的
Jin Wang1, Hong-Juan Wei2, Rui-Feng Mao3
1Department of Ultrasound Medicine, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, Jiangsu Province, China.
World journal of diabetes
|November 4, 2024
概括
改变肠道微生物群 (GM) 显示出糖尿病 (DM) 预防和治疗的希望. 然而,对于有效的转基因向疗法,需要明确的因果关系和个性化方法.
科学领域:
- 内分泌学 在内分泌学.
- 微生物学 微生物学
- 代谢疾病 代谢疾病
背景情况:
- 新兴研究突出显示了肠道微生物群在糖尿病 (DM) 发病过程中的作用.
- 许多动物研究表明存在联系,但人类数据和机械学理解仍然有限.
研究的目的:
- 批判性地评估有关肠道微生物群调节的最新发现,以预防和管理糖尿病.
- 强调需要机制清晰和个性化治疗策略的需要.
主要方法:
- 编辑评论了最近在"世界糖尿病杂志"上发表的两篇文章.
- 综合有关肠道微生物群和糖尿病的现有文献.
主要成果:
- 肠道微生物群对DM的参与被建议但尚未完全阐明.
- 目前修改DM肠道微生物群的干预措施往往缺乏长期数据和机制性见解.
结论:
- 肠道微生物群的修饰具有治疗糖尿病的潜力.
- 个体的变化需要个性化,机械驱动的干预措施,以获得最佳的结果.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
321
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
321
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Inflammatory Bowel Disease IV: Pharmacological Management
116
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
116
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
What is Monogastric Digestion?
70.6K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
70.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175


